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 Several categories of bone graft and graft substitutes 
exist and encompass a variety of materials, material 
sources, and origins. The available graft substitutes 
formed from composites of one or more types of 
material. These composites are generally built on a 
base material. Laurencin et al1 classification of grafts 
and graft substitutes could be modified as follows: 
A. Harvested bone grafts and graft substitutes: 
bone grafts, endogenous or exogenous, are often 
essential to provide support, fill voids, and enhance 
biologic repair of skeletal defects due to traumatic 
or non-traumatic origin. Limitations of use of 
endogenous bone substance involve additional 
surgery; often resulting donor site morbidity and 
limited availability2-4 where as allograft have been 
encountered with risk of disease transmission, 
immunogenicity5. Therefore, there is a growing 
need for synthesis of allograft bone substitutes 
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Treatment of delayed union, malunion, and nonunion is a challenge to the orthopaedic surgeons in 
veterinary and human fields. Apart from restoration of alignment and stable fixation, in many cases 
adjunctive measures such as bone-grafting or use of bone-graft substitutes are of paramount importance. 
Bone-graft materials usually have one or more components: an osteoconductive matrix, which acts as 
scaffold to new bone growth; osteoinductive proteins, which support mitogenesis of undifferentiated cells; 
and osteogenic cells, which are capable of forming bone in the appropriate environment. Autologous bone 
remains the “gold standard” for stimulating bone repair and regeneration, but its availability may be 
limited and the procedure to harvest the material is associated with complications. Bone-graft substitutes 
can either substitute autologous bone graft or expand an existing amount of autologous bone graft. We 
review the currently available bone graft and graft substitutes for the novel therapeutic approaches in 
clinical setting of orthopaedic surgery.
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used alone or in combination with other materials 
(e.g., Allogro [AlloSource, Centennial, Colo], 
Opteform [Exactech, Inc, Gainesville, Fla], Grafton 
[BioHorizons, Birmingham, Ala], OrthoBlast 
[IsoTis OrthoBiologics, Irvine, Calif]).
B. Growth factor-based bone graft substitutes: 
natural and recombinant growth factors used 
alone or in combination with other materials such 
as transforming growth factor-beta (TGF-beta), 
platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), and bone morphogenetic 
protein (BMP). 
C. Cell-based bone graft substitutes: use cells to 
generate new tissue alone or are seeded onto a 
support matrix (e.g., mesenchymal stem cells). 
D. Ceramic-based bone graft substitutes: include 
calcium phosphate, calcium sulfate, and bioglass 
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used alone or in combination (e.g., OsteoGraf 
[DENTSPLY Friadent CeraMed, Lakewood, Colo], 
Norian SRS [Synthes, Inc, West Chester, Pa], 
ProOsteon [Interpore Cross International, Irvine, 
Calif], Osteoset [Wright Medical Technology, Inc, 
Arlington, Tenn]). 
E. Polymer-based bone graft substitutes: degradable 
and nondegradable polymers, are used alone 
or in combination with other materials (e.g., 
Cortoss [Orthovita, Inc, Malvern, Pa], open 
porosity polylactic acid polymer [OPLA], Immix 
[Osteobiologics, Inc, San Antonio, Tex]).
F. Miscellaneous: Various unconventional marine 
biomaterials are also in use as bone graft substitute 
which includes coral, chitosan, sponge skeleton 
etc.
 Bone grafts and their substitutes can also be divided 
into osteoinductive agents, osteoconductive agents and 
osteogenic agents. 
Osteoinductive agents are generally proteins, • 
which induce differentiation of undifferentiated 
stem cells to osteogenic cells or induce stem cells 
to proliferate6.
Osteoconduction is the process whereby • 
microscopic and macroscopic scaffolding is 
provided for inward migration of cellular elements 
involved in bone formation (e.g., mesenchymal 
cells, osteoblasts, osteoclasts, and vasculature). 
Osteogenesis in a general sense, osteogenesis refers • 
to bone formation with no indication of cellular 
origin: new bone may originate from live cells in 
the graft or cells of host origin. 
 Many other classification systems of graft and 
graft substitute also exist. However, in this review the 
modification of Laurencin et al1 is followed. The past 
and existing bone grafts, graft substitutes and the clinical 
evidence to support their use in the management of 
orthopaedic cases are reviewed as also future direction 
of research (Table).
A. Harvested bone grafts and graft substitutes:
1. Bone grafts:
I.I. Autogenous bone grafts (Bone autografts)
 Autogenous bone grafts are considered as the gold 
standard for bone replacement, mainly because they 
offer minimum immunological rejection, complete 
histocompatibility and provide the best osteoconductive, 
osteogenic and osteoinductive properties7. Autografts 
usually contain viable osteogenic cells, bone matrix 
proteins and support bone growth8 which are obtained 
from vascularized and non vascularized cortical 
and autologous bone marrow grafts. They offer 
Table. Bone graft and graft substitutes
Class Description Examples Properties of action
Autograft based Used alone Osteoconductive•	
Osteoinductive•	
Osteogenic•	
Allograft based Allograft bone used alone or in combination 
with other materials
Allegro, Orthoblast, Grafton Osteoconductive•	
Osteoinductive •	
Factor based Natural and recombinant growth factors used 
alone or in combination with other materials
TGF-β, PDGF, FGF, BMP Osteoinductive•	
Both osteoconductive and •	
osteoinductive with carrier 
materials
Cell based Cells used to generate new tissue alone or 
seeded onto a support matrix
Mesenchymal stem cells Osteogenic, •	
Both osteogenic and •	
osteoconductive with carrier 
materials
Ceramic based Includes calcium phosphate, calcium 
sulfate, and bioactive glass used alone or in 
combination
Osteograf, , Osteoset, 
NovaBone
Osteoconductive•	
Limited osteoinductive when •	
mixed with bone marrow
Polymer based Includes degradable and nondegradable 
polymers used alone and in combination with 
other materials 
Cortoss, OPLA, Immix Osteoconductive•	
Bioresorbable in degradable •	
polymer
Miscellaneous Coral HA granules, blocks and composite ProOsteon Osteoconductive•	
Bioresorbable •	
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structural support to implanted devices and ultimately 
become mechanically efficient structures as they are 
incorporated into surrounding bone through creeping 
substitution9. They also suffer from resorption, limited 
availability and viability.
 Autologous cancellous bone graft has been 
considered more osteogenic as compared to cortical 
bone graft because the presence of spaces within their 
structure, allows the diffusion of nutrients and limited 
revascularization by microanastomosis of its circulating 
vessels10-12. Cancellous graft is good space filler, but 
it does not provide substantial structural support. As 
only the osteoblasts and endosteal cells on the surface 
of the graft survive the transplant, a cancellous graft 
acts mainly as an osteoconductive substrate, which 
effectively supports the ingrowth of new blood vessels 
and the infiltration of new osteoblasts and osteoblasts 
precursors13. Further, an osteoprogenitor cell, however, 
is a mesenchymal cell that has acquired the ability to 
create cells with osteogenic capabilities.  Transfer of a 
single osteoprogenitor cell can, through propagation, 
produce possibly hundreds of osteoblasts, and thus a 
considerable amount of bone.  The principle advantage 
of autologous cancellous grafts is the potential to 
transfer osteoprogenitor cells to the recipient site. 
Osteoinductive agents, such as bone morphogenic 
protein (BMP), have varying abilities to induce 
mesenchymal cells to transform to osteoprogenitor cells 
and thus produce bone. Cancellous graft does not provide 
immediate structural support, it integrates quickly and 
ultimately achieves strength equivalent to cortical graft 
within six to twelve months14. Osteoinductive factors 
released from the graft during the resorptive process 
as well as cytokines released during the inflammatory 
phase may also contribute to the healing of the wound, 
this is only based on circumstantial evidence; not yet 
been substantiated by scientific documentation13,15. 
It has been observed that weight bearing capacity of 
affected limb returned earlier in animals with autograft 
compared to other types of bone grafts used16. In an 
experimental study dog, it was observed that fresh 
autogenous bone grafts are incorporated rapidly and 
possess osteoinductive, osteoconductive and osteogenic 
properties17. Autologous cancellous bone is commonly 
harvested from iliac crest, sometimes from the distal 
part of the radius/ tibia. It is widely used for delayed 
union of long bone fractures and reconstruction of 
depressed fracture of lateral tibial plateau18-20. 
 Autologous cortical grafts have little or 
no osteoinductive properties and are mostly 
osteoconductive, but the surviving osteoblasts do 
provide some osteogenic properties as well21,22. Non-
vascularized cortical grafts provide immediate structural 
support; they become weaker than vascularized cortical 
grafts during the initial six weeks after transplantation 
as a result of resorption and revascularization21-23. 
Vascularized cortical grafts heal rapidly at the host-
graft-interface, and their remodeling is similar to that 
of normal bone. On the contrary, nonvascularized 
grafts do not undergo resorption and revascularization 
and, therefore, they provide superior strength during 
the first six weeks21. Despite their initial strength, 
cortical graft still must be supported by internal 
or external fixation to protect them from fracture. 
Autologous cortical bone grafts are good choices for 
segmental defects of bone of > 5 to 6 cm, which require 
immediate structural support. Larger graft requires 
prolonged time for resorption and fracture of graft 
may ensue if osteogenesis is not proper. On the other 
hand, if a bone graft is fragmented into small particles, 
even cancellous bone is killed and will no longer be 
osteogenic24,25. The main advantages of autologous 
cancellous graft are their excellent success rate and low 
risk of disease transmission. However, disadvantages 
as cited above include potential morbidity at the donor 
site, availability in limited quantities, and risk of 
wound infection, increased blood loss and prolonged 
anaesthetic time26,27.
 Site of grafting is another important factor 
influencing osteogenesis. Resorption and replacement 
of a bone graft in a skeletal bed occurs more rapidly 
at the end of a long bone (cancellous) than at the 
center of shaft (cortical bone)24,28. Accurate contact 
between a cortical bone graft and its bed is utmost 
necessary. Bone to bone contact along with low-
intensity pulsed ultrasound LIPUS are also necessary 
in the treatment of delayed union or filling a skeletal 
defect with percutaneous bone grafts29,30. Ultrasound 
has a significant effect on biological tissues and cells 
involved in bone healing and in fracture repair and 
data from the literature support a positive effect on 
osteogenesis of LIPUS, applied percutaneously, in 
different experimental and clinical settings. LIPUS 
significantly stimulates and accelerates fresh fracture 
healing and is effective in promoting bone healing 
in aseptic and septic delayed- and nonunions with a 
healing rate ranging from 70 to 93 per cent in different, 
nonrandomized, studies. Advantages of the use of this 
technology is that it may avoid the need for additional 
complex operations for the treatment of nonunions 
include efficacy, safety, ease of use and favourable 
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cost/benefit ratio. Outcome depends on the site of 
nonunion; time elapsed from trauma, stability at the 
site of nonunion and host type28. Percutaneous bone 
grafting appeared to be as effective as open techniques, 
and possessed considerable advantages. It is safe, time 
saving and economical, it involves minimal trauma 
at the fracture site and it avoids major donor site 
problems29.
 Time interval between procurement and 
transplantation of graft is also an important factor31. 
Autogenous bone grafts retained their viability for 
two hours when kept in normal saline32. Coupland 
concluded that the graft remained unchanged in shape 
and act as a passive scaffold for new bone growth to fill 
the defect even after autoclaving33. In another study34 
freeze drying of autogenous bone did not alter the 
normal repair process associated with fresh autografts.
I.II. Bone marrow
 Bone marrow has been used to stimulate bone 
formation in skeletal defects and nonunion through 
cytokines and growth factors secreted by the transplanted 
cells35. The main advantage of this technique is that it 
can be performed percutaneously, without almost any 
patient morbidity. Centrifugation of aspirated bone 
marrow at 400 times gravity for ten minutes separates 
the marrow cells from plasma and preserves the 
osteogenic potential of the cells, decreasing the volume 
of material injected36. Proliferation and differentiation 
of stem cells may be increased by adding them into 
growth factors37 or by combining them in collagen38.
 The volume of bone marrow to be injected has been 
more controversial. The larger the volume of aspirate the 
grater number of alkaline phosphatase- positive colony 
forming units but they are more diluted39. Connolly et 
al36 have recommended centrifugation of the aspirate 
to increase the percentage of cells and the efficacy of 
the aspirate. Curylo et al40 have reported good results 
as a graft extender (insufficient autograft augmented 
with bone marrow) in experimental posterolateral spine 
fusion.
 Autologous bone marrow mixed with 10 mg of 
demineralized bone matrix has been successfully used 
to fill bone defects35,41 as demineralized bone matrix is 
an excellent carrier because of its osteoinductive as well 
as osteoconductive properties. Injection of autologous 
bone marrow, with or without a carrier, has been used 
to treat nonunion and delayed union of several bones. 
However, it does not promote healing more rapidly or 
to a greater extent than do traditional bone grafting 
techniques42,43. 
I.III. Allogenic bone grafts
 The limitations associated with the procurement of 
autograft for bone grafting can be overcome by the use 
of allografts. Allograft bone is referred to as cadaver, 
obtained from donor bone and has both osteoinductive 
(they release bone morphogenic proteins that act 
on bone cells) and osteoconductive properties, but 
lack osteogenic properties because of the absence of 
viable cells44. However, harvesting and conservation 
of allogenic grafts are additional limiting factor28,45,46. 
The major advantage of allograft bone harvested from 
cadaver sources include its ready availability in various 
shapes and sizes, avoidance of the need to sacrifice 
host structures, and no donor site morbidity. Still, there 
is some controversy regarding association of allograft 
bone with the transmission of infectious agents, a major 
concern virtually eliminated through tissue-processing 
and sterilization. 
 Allogenic bone is available in many forms: 
demineralized bone matrix, morselized and cancellous 
chips, corticocancellous and cortical grafts, and 
osteochondral and whole-bone segments.
II. Demineralized bone matrix (DBM):
 Demineralized bone matrix (DBM) which 
has been shown to have an osteoconductive and 
osteoinductive potential47-51 is an interesting option. 
DMB provides no structural strength, and its primary 
use is in a structurally stable environment. DBM also 
revascularizes quickly and acts as suitable carrier 
for autologous bone marrow. It does not evoke any 
appreciable local foreign body immunogenic reaction 
as antigenic surface structure of bone is destroyed 
during demineralization52. The biologic activity of 
demineralized bone matrix is presumably attributable 
to proteins and various growth factors present in the 
extracellular matrix and made available to the host 
environment by the demineralization process. The 
osteoinductive capacity of demineralized bone matrix 
can be affected by storage, processing, and sterilization 
methods and can vary from donor to donor.
 DMB has been successfully used to induce bone 
formation in various clinical conditions viz., to fill the 
defects caused by bone cysts and cavities41,53,54, Cranio-
maxillofacial reconstruction55, bridging of large bone 
defects and repair of high risk fracture50 and even very 
high risk defects56. The most successful grafts may 
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be composites of DMB bone matrix and autologous 
bone marrow35,41 in stable fixation cases and human 
DMB with calcium sulfate (CaSO4) in displaced intra-
articular calcaneal fractures58. DMB can also augment 
and expand autologous cancellous bone graft when the 
supply of autogenous bone is limited or the defect is 
very large. 
 DMB has several potential disadvantages. Because 
it is an allergenic material, there is the potential to 
transmit human immunodeficiency virus (HIV). 
Another possible limitation of demineralized bone 
matrix is that different batches may have different 
potencies because of the wide variety of donors used to 
supply the graft.
B. Growth factor-based bone graft substitutes
Bone growth factors
 The clinical use of growth factors is mainly limited 
by the problem of delivery58. Insulin like growth factor 
(IGF-1) and TGFβ mostly modulate the synthesis of 
the cartilage matrix59,60 while basic fibroblast growth 
factor (bFGF) has a powerful mitogenic factor which 
stimulates the differentiation of chondrocytes61,62. 
Platelet-derived growth factor (PDGF) was studied 
on the bone healing of unilateral tibial osteotomies in 
rabbits and revealed that it had a stimulatory effect on 
fracture healing63. Basic fibroblast growth factor (bFGF) 
is produced locally in bone during the initial phase of 
fracture healing and is known to stimulate cartilage 
and bone forming cells64. Vascular endothelial growth 
factor, which combined with a coralline scaffold either 
coated with a control-plasmid DNA (a small cellular 
inclusion consisting of a ring of DNA that is not in a 
chromosome but is capable of autonomous replication), 
VEGF-plasmid DNA, loaded with mesenchymal stem 
cells (BMSC) transfected with control plasmid or 
with both stem cells and the VEGF plasmid showed 
to improve healing in large bone defects, in which 
bone substitutes will otherwise not be vascularized 
and replaced by fresh bone65. The application of 
gene transfer, which is a new technology, represents 
a unique opportunity for the local administration of 
growth factors58,66. Bone morphogenetic proteins 
(BMPs) are biologically active molecules capable 
of inducing new bone formation, and show potential 
for clinical use in bone defect repair. The synthetic 
biodegradable polymer/ interconnected-porous 
calcium hydroxyapatite ceramics (IP-CHA) composite 
is an excellent combination carrier/scaffold delivery 
system for recombinant bone morphogenetic protein-2 
(rhBMP-2), that strongly promotes the clinical effects 
of rhBMP-2 in bone tissue regeneration67. 
C. Cell-based bone graft substitutes:
I. Stem cell 
 Stem cell research attracts considerable attention 
because the ethical controversies associated with 
the destruction of human embryos and the clinical 
potential of embryonic stem cells in regenerative and 
reparative therapies. Stem cell is an ‘immature’ or 
undifferentiated cell which is capable of producing 
any identical daughter cells68,69. The main sources of 
stem cells include somatic (Adult) and embryonic stem 
cells. Somatic stem cells include haematopoietic stem 
cells, bone marrow stromal (Mesenchymal) stem cells 
(MSC)68,70, neural stem cells71, dermal (Keratinocytes) 
stem cells72, stem cells from fetal cord blood73 and 
several others. The best options are those derived 
from the bone marrow which yields two types, the 
haematopoietic stem cells which gives rise to the entire 
blood cell lineage and the mesenchymal stem cells 
from which are derived various connective tissues 
such as bone and adipose tissues. Mesenchymal stem 
cells have also been identified and currently being 
used for the repair and regeneration of bone, cartilage, 
muscle, tendon and ligament74. Embryonic stem cells 
in mice have been used to generate a range of distinct 
phenotype including haematopoietic precursor75, 
neural cells76, adipocytes77, muscle cells78, myocytes79, 
chondrocytes80, pancreatic islets81 and osteoblast82. 
 The means of delivering factors to stimulate stem 
cells in vivo to initiate a process leading to regeneration 
has long been sought. Success has been restricted by 
problems of dosage, lack of full activity of recombinant 
factors and the inability to sustain the presence of the 
factor for an appropriate length of time. ‘Gene-activated 
matrices’ are being investigated which compromise 
plasmids coding for factors in a variety of delivery 
vehicles. Fresh marrow cells or cultured mesenchymal 
stem cells (MSCs) combined with porous ceramic 
and implanted into rat83,84 or canine segmental bone 
defects85 have shown osteogenic potential. Repair of 
cartilage damage or defects is technically challenging 
because cartilage tissue is relatively thin and avascular. 
In an attempt to provide regeneration of both cartilage 
and bone, cultured MSCs were implanted into massive 
osteochondral defects in the medial condyle of the distal 
femur of young adult rabbits. The MSCs uniformly 
formed chondrocytes which served to resurface the 
condyle86,87.
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 Despite the challenges of isolating, expanding and 
defining stem cell populations, they hold tremendous 
promise for tissue regeneration at a clinically useful 
level. There are several examples of the potential use 
of stem cells in regenerative medicine, but, a thorough 
research in this area is needed to characterize graft 
versus host stem cells immune interactions and to 
identify mechanisms enabling the delivery or homing of 
the stem cells to the site of interest in clinical context.
II. Collagen 
 Collagen as an osteoinductive material is due 
to its osteoconductive property and when it is used 
in combination with osteoconductive carriers like 
hydroxyapatite or tricalcium phosphate. These 
composites are mixed with autologous bone marrow 
which subsequently provides osteoprogenitor cells 
and other growth factors. Chapman et al88 conducted 
a prospective, randomized comparison of autologous 
iliac crest bone graft and calcium-collagen graft 
material in the treatment of acute long-bone fractures 
with both bone-grafting (<30 cm3 volume required) and 
internal or external fixation. The authors88 observed no 
differences between the two groups with regard to the 
union rate or functional measures, and they concluded 
that calcium-collagen graft material with autologous 
bone marrow can be used instead of autologous bone 
graft for patients who have an acute traumatic defect of 
a long bone. There is no scientific proof that calcium-
collagen graft materials can effectively substitute for 
autologous bone graft to stimulate healing of nonunion. 
This material with autologous bone marrow can be 
used as a replacement for autologous bone graft for 
acute long-bone fractures with enough comminution or 
cortical bone loss to require bone-grafting when internal 
or external fixation is planned26. It is not recommended 
to fill metaphyseal bone defects resulting from articular 
fractures as it does not offer structural support and also 
for the treatment of nonunion except in the role of a 
bone-graft expander when the supply of autologous 
bone graft is limited26.
III. Gene therapy
 Gene therapy involves the transfer of genetic 
information to cells. When a gene is transferred to a 
target cell, the cell synthesizes the protein encoded 
by the gene. For gene expression, the transferred 
DNA material must enter the nucleus where it can be 
transcripted. After transcription, the generated m-RNA 
is transported outside the nucleus and serves as a 
matrix for the production of proteins in the ribosome. 
The gene therapy used for gene induction is short-term 
and as regional therapy. The gene can be introduced 
directly to specific anatomic site (in-vivo technique) 
or specific cells can be harvested from the patient, 
expanded, genetically manipulated n tissue culture and 
then reimplanted (ex-vivo technique). Generally, the 
direct method is less technically demanding, indirect 
gene delivery is safer, because, the gene manipulation 
takes place under controlled conditions outside the 
organism. Viral and non-viral vectors can be used for 
the delivery of genetic materials into cells. Non-viral 
gene transfer systems such as liposomes, naked DNA 
are usually easier to produce and have a lower toxicity 
and immunogenicity, but the efficiency of their gene 
delivery is impeded by a blow rate of infection unless 
the transduced cells are selected89,90. Recently, viral 
gene vectors, including retrovirus, adenovirus, adeno-
associated virus and herpes virus are more efficient 
method of gene transfer91. 
 Tomita et al92 first reported successful delivery 
of genes into the articular cartilage using a 
haemagglutinating virus (HVJ; sendai virus) liposome 
suspension containing the SV40 large T antigen (SVT) 
gene which was injected intra-articularly into the 
knees of rats. Biological effect of an effective growth 
factor in cartilage healing was studied using rabbit 
mesenchymal stem cells transduced with retroviral 
vectors encoded for the gene of bone morphogenetic 
protein-7, seeded on polymer scaffold grafts implanted 
into osteochondral defects in rabbit knees93.
D. Ceramic-based bone graft substitutes
 Among different ceramic based graft substitute 
materials, calcium phosphate based ceramics such as 
hydroxyapatite (HA), β-tricalcium phosphate (β-TCP) 
and bioactive glass are used quite substantially for 
long time. Calcium phosphate ceramics are synthetic 
scaffolds that have been used in dentistry since the 
early 1970s and in orthopedics since 1980s94-97.
I. Calcium hydroxyapatite (HAp)
 Hydroxyapatite is a biocompatible ceramic 
produced through a high-temperature reaction and 
is highly crystalline form of calcium phosphate. The 
nominal composition of this mixture is Ca10 (PO4)6 
(OH) 2 with a calcium-to-phosphate atomic ratio of 
1.67. The most unique property of this material is 
chemical similarity with the mineralized phase of 
bone; this similarity accounts for their osteoconductive 
potential and excellent biocompatibility98-100. Calcium 
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hydroxyapatite/tricalcium phosphate (60/40) provide a 
structure or scaffold which can have a close interface 
with adjacent bone and have a limited application in 
the treatment of load-bearing segmental bone defects 
but did not fail at the early stages of implantation101. 
Hydroxyapatite has been established to be an excellent 
carrier of osteoinductive growth factors and osteogenic 
cell populations, which greatly add to their utility as 
bioactive delivery vehicles in the future102.
 The ideal pore size for a bioceramic should be similar 
to that of spongious bone. It has been demonstrated 
that microporosity (pore size <10 μm) allows body 
fluid circulation whereas macroporosity (pore size 
>50 μm) provides scaffold (Pore size-100-200 μm and 
porosity-60-65%) for bone-cell colonization103,104. An 
ideal pore size diameter of 565 μm is reported as the 
ideal macropore size for bone ingrowth compared to 
a smaller size (300 μm)105. However, in another study 
by Kuhne et al106 the optimal size of the pores was 
found to be 500 µm. In an experimental study in goats 
with porous calcium phosphate ceramics, Toth et al107 
found that the ceramic when mixed with autograft in 
the ratio of 70 (ceramic): 30 (autograft) were effective 
for anterior cervical interbody fusion, Johnson et al108 
found that hydroxyapatite alone gave poor results. The 
interconnected high porous structure of hydroxyapatite 
seems to be promising for the environment of 
posterolateral lumbar intertransverse process spine 
fusion (PLF) in the point of producing fusion mass 
with higher cellular viability109,110.
 During recent years, there have been efforts in 
developing doped bioceramics materials to enhance 
their mechanical and biological properties as well 
as cytocompatibility for use in tissue engineering 
applications111,112. Hydroxyapatite (HA) as a 
synthetic material, usually used as coating for dental 
and orthopedic implants, are known for its good 
cytocompatibility properties, but is limited in use due 
to its moderate to low solubility within the body and 
mechanical properties that differ from surrounding 
tissue and bone111. Doped HA with manganese and/or 
zinc as bone substitute have been tried and resulted in 
faster resorption kinetics113.
 Plasma spray HA coating has been used on 
metallic femoral stem and cup as a means of fixation 
in order to avoid complications related to the use of 
PMMA114. Hydroxyapatite-coated pins enhance pin 
fixation regardless of bone type and loading conditions 
and reduces the rate of infection and loosening during 
external fixation115,116. Nguyen et al117 studied the effect 
of sol-gel-formed calcium phosphate coatings on bone 
ingrowth and osteoconductivity of porous-surfaced 
Ti alloy implants in rabbit tibia and observed that 
endosteal bone growth along the porous-surfaced zone 
was greater with the Ca-P-coated implants compared 
to the non Ca-P-coated implants and greater bone-to-
implant contact within the sinter neck regions of the 
Ca-P-coated implants. 
II. Tri-calcium phosphate (TCP)
 Like hydroxyapatite, TCP is bioabsorbable 
and biocompatible. The chemical composition and 
crystallinity of the material are similar to those of the 
mineral phase of bone. The nominal composition of 
TCP is Ca3 (PO4)2. It exists in either α or β-crystalline 
forms. The rate of biodegradation is higher when 
compared with HA. Degradability occurs by combined 
dissolution and osteoclastic resorption103.
 Tricalcium phosphate implants have been used for 
two decades as synthetic bone void fillers in orthopaedic 
and dental applications95,118. The small particle size and 
interconnected sponge like microporosity are believed 
to improve osteoconductive properties and promote 
timely resorption concomitant with the process of 
remodeling100,119-121. Zhang et al122 reported bone 
formation with bone marrow stromal cells (BMSCs) 
and β-tricalcium phosphate (β-TCP) as bone substitute 
implanted in rat dorsal muscles. Cutright et al123 
found 95 per cent absorption of tricalcium phosphate 
ceramic implants in rat tibias 48 days postoperatively 
with extensive bone growth and marrow reformation. 
Cameron et al124 observed both the toxicity and the 
bone-ingrowth potential of TCP in canine model and 
reported no untoward tissue or systemic reaction 
when implanted in cancellous bone; it was rapidly 
infiltrated with bone and slowly resorbed. Breitbart 
et al125 conducted experimental trials with TCP 
ceramic and osteogenin, an osteoinductive protein as 
an onlay graft substitute in a rabbit calvarial model. 
Gao et al126 evaluated the effects of biocoral and TCP 
cylinders in segmental tibial bone defects (16 mm in 
length) and observed that biocoral is superior to TCP 
in repair of segmental defects in weight bearing limbs. 
Recombinant human bone morphogenetic protein 
(rhBMP)-2 with beta-TCP is a promising composite 
having osteogenicity and efficient enough for repairing 
large bone defects127.
III. Bioactive glass
 Bio-active glass ceramics (Bioglass) were 
first developed by Hench et al128. This glass is 
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biocompatible, osteoconductive and bonds to bone 
without an intervening fibrous connective tissue 
interface129,130. This material has been widely used for 
filling bone defects100,131,132 alone and in combination 
with autogenous and allogenic cancellous bone graft133. 
Bioglass is composed mainly of silica, sodium oxide, 
calcium oxide and phosphates.
 The bone-bonding reaction results from a 
sequence of reactions in the glass and its surface134. 
After long-term implantation, this biological apatite 
layer is partially replaced by bone135. The behaviour 
of bioactive glasses is dependent on the composition 
of the glass136,137, the surrounding pH, the temperature, 
and the surface layers on the glass138,139. The porosity 
provides a scaffold on which newly-formed bone can 
be deposited after vascular in growth and osteoblast 
differentiation. The porosity of bioglass is also 
beneficial for resorption and bioactivity140. 
 In experimental cancellous bone defects in rat 
models, bioglass was found biocompatible, and the 
filler effect was greater with bioactive glass than with 
autogenous bone141. Bioglass was found to trigger new 
bone formation by allogenic demineralized bone matrix, 
and the biocompatibility of the glass was verified by 
the absence of adverse cellular reactions142,143. Bone-
bonding response significantly enhanced with the 
microroughening of the bioactive glass surface, but 
the glass composition affected the intensity of the 
response144. In another study, the microroughening of 
the bioglass surface accelerated temporal changes in 
the expression of specific genes involved in the bone 
healing process145. Bioactive glasses have shown no or 
only mild inflammatory responses in the surrounding 
tissue in histological in vivo studies and in 6 months, 
the glass fiber scaffolds are completely resorbed146.
 Bioactive glasses have been clinically used for 
tympanoplastic reconstruction147, as filling material in 
benign tumour surgery148, for reconstruction of defects 
in facial bones149,150, for treatment of periodontal bone 
defects151,152, in obliteration of frontal sinuses153-155, in 
repairing orbital floor fractures156,157, in lumbar fusion158, 
and for reconstruction of the iliac crest defect after bone 
graft harvesting159. 
IV. Calcium phosphate cement
 Calcium phosphate ceramics introduced more than 
three decades ago are considered as bioactive bone 
substitutes. The paste or injectable calcium phosphates 
cement offers the advantage of being freely mouldable 
and adaptable to bone defects. Brown and Chow160,161 
first reported the formation of apatitic cement consisting 
of a mixture of tetracalcium phosphate (TetCP) and 
dicalcium phosphate anhydrite (DCPA). Grüninger et 
al162 introduced the term “calcium phosphate cements 
(CPC)” and described as: ‘a powder or as a mixture of 
powders which, upon mixing with water or an aqueous 
solution to a paste, reacts around room or body 
temperature by the formation of a precipitate containing 
crystals of one or more calcium phosphates and sets by 
the entanglement of the crystals of that precipitate’163. 
After implantation, this composition form HAp in 
situ in contact with the physiological fluid. Since its 
inception CPCs have attracted much attention and 
different formulations have been put forward164-168.
 The drawback in using these materials was that 
close proximity to the host bone was necessary to 
achieve osteoconduction. Even, when this is achieved, 
new bone growth is often strictly limited because these 
materials are not osteoinductive in nature. To overcome 
this limitation, a number of different bone derived-
growth factors have been demonstrated to stimulate 
bone growth, collagen synthesis and fracture repair 
both in vitro and in vivo. 
 The combination of high biocompatibility, easy-
to-shape characteristic, and the capacity to self-setting 
under ambient conditions makes it an asset in the 
repair of hard tissue defects169-172 and research and 
development on CPC have attracted much attention 
in recent years172-175. Based on its flow behavior 
before setting of slurry, CPC has been used as a root 
sealer-filler176 and as an injectable biomaterial177-181 
for bone replacement, especially in percutaneous 
vertebroplasty182-184 and kyphoplasty185-187. Šiniković et 
al188 investigated the potential of CPC in the treatment 
of orbital wall defect fractures in an adult sheep model 
and compared the same with autologous calvarias 
split-bone grafts. However, CPC also suffers from its 
inherent lack of microporosity for tissue invasion189 
and poor injectibility190. Pore size and inherent strength 
play a major role in the ultimate usefulness of calcium 
phosphate cement. The pore size of Bone Source, a 
prototype CPC, has been reported to be as small as 
2-5 nm191 to as large as 8-12 μm189, unsuitable for this 
particular application. Earlier it was generally believed 
that calcium phosphate cements are reabsorbed with 
bone formed via osteoconduction, but, recent studies 
suggested that calcium phosphate cements directly 
initiate osteogenesis189. Although the mechanism of 
osteoinduction remains unclear, the ionic exchanges 
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properties of the calcium phosphate cement with the 
surrounding milieu have been pointed out as a relevant 
parameter, among others. High microporosity in CPC 
is directly correlated with the exposed surface, and 
therefore an elevated dissolution in the pores where 
the level of stable critical level of free calcium ions 
and possibly free orthophosphate ions might trigger 
cell differentiation into osteogenic lineage. In addition, 
through a dissolution–precipitation process, the 
development of a bone-like mineral layer might initiate 
bone formation either by mimicry with the bone mineral 
structure or by the presence of osteogenic compounds 
(for example bone morphogenetic proteins) contained 
naturally in body fluids that might have concentrated at 
the newly formed mineral layer. 
V. Calcium Sulfate:
 Calcium sulfate graft material with a patented 
crystalline structure described as an alphahemihydrate 
acts primarily as osteoconductive bone-void filler that 
completely resorbs as newly formed bone remodels and 
restores anatomic features and structural properties. 
Potential application of calcium sulfate graft material 
includes the filling of cysts, bone cavities192, benign 
bone lesions193 and segmental bone defects; expansion 
of grafts used for spinal fusion; and filling of bone-
graft harvest sites26. It is biocompatible, bioactive 
and resorbable after 12 wk194. Significant loss of its 
mechanical properties occurs upon its degradation; 
therefore, it is a questionable choice for load-bearing 
applications.
E. Polymer-based bone graft substitutes
 Polymers present some options that the other groups 
do not. Like many polymers are potential candidates 
for bone graft substitutes represent different physical, 
mechanical, and chemical properties. The polymers 
used today can be loosely divided into natural polymers 
and synthetic polymers. These, in turn, can be divided 
further into degradable and nondegradable types.
Polymer-based bone graft substitutes include the 
following:
 Healos (DePuy Orthopaedics, Inc, Warsaw, 
Ind) is a natural polymer-based product, a polymer-
ceramic composite consisting of collagen fibers 
coated with hydroxyapatite and indicated for spinal 
fusions195. Cortoss is an injectable resin-based product 
with applications for load-bearing sites196. Rhakoss 
(Orthovita, Inc) is a resin composite available as a solid 
product in various forms for spinal applications196. 
Degradable synthetic polymers, like natural polymers, 
are resorbed by the body. The benefit of having the 
implant resorbed by the body is that the body is able to 
completely heal itself without remaining foreign bodies. 
To this end, companies have used degradable polymers 
such as polylactic acid and poly (lactic-co-glycolic 
acid) as stand-alone devices and grafted with grafted 
hyaluronic acid for periodontal barrier applications197. 
BoneTec, Inc (Toronto, Canada) has developed a 
porous poly (lactic-co-glycolic acid) foam matrix by 
using a particulate leaching process to induce porosity. 
Immix Extenders (Osteobiologics, Inc), a particulate 
poly (lactic-co-glycolic acid) product, is used as a graft 
extender.
F. Miscellaneous
I. Coral 
 Chiroff et al198 first observed that corals from 
marine invertebrates have skeletons with a structure 
similar to both cortical and cancellous bone, with 
interconnecting porosity. Coralline hydroxyapatite is 
processed by a hydrothermal exchange method that 
converts the coral calcium phosphate to crystalline 
hydroxyapatite with pore diameters between 200 
and 500 μm and in a structure very similar to that of 
human trabecular bone. Bucholz et al199 reported that 
the clinical performance of autologous cancellous bone 
graft and coralline hydroxyapatite are similar during 
filling of bone voids resulting from articular surface 
depression in tibial plateau fractures. More recently, 
coralline hydroxyapatite has been used as a carrier for 
some bone derived growth factors. It has been used as 
a carrier for BMP with success in rabbit model and as 
a carrier for transforming growth factors and fibroblast 
growth factors in a rabbit model200. To avoid donor 
site morbidity, coralline hydroxyapatite granules or 
blocks of various size, depending on the size of the 
defect can be used to fill metaphyseal defects after 
reduction of depressed articular segments26. Coralline 
hydroxyapatite bone graft substitute appears to be a 
clinically effective material for use in foot procedures 
although the slow resorption is a concerning 
characteristic of the graft material without any adverse 
effect201. Another contraindication to the use of this 
material is a joint surface defect that would allow the 
grafting material to migrate into the joint.
II. Chitosan and Sponge skeleton:
 Over the past three decades, an enormous array 
of biomaterials proposed as ideal scaffolds for cell 
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growth have emerged, yet few have demonstrated 
clinical efficacy. Natural marine sponge skeletons202 
and chitosan203 have proved as effective biomaterials 
for modern tissue engineering. The abundance and 
structural diversity of natural marine sponge skeletons 
and their potential as multifunctional, cell conductive 
and inductive frameworks along with collagenous 
composition of the fiber indicate a promising new 
source of scaffold for tissue regeneration204. Chitosan, 
a natural product derived from the polysaccharide 
chitin (Aminopolysaccharide; combination of 
sugar and protein), an abundantly available natural 
biopolymer found in the exo-skeletons of crustacean 
like shrimp, crabs, lobster and other shellfish would be 
an effective material to repair bone defects due to its 
biocompatibility203. In an experimental study, natural 
hydroxyapatite/chitosan composite were evaluated 
in reconstruction of bone defects and observed 
that this composite has good biocompatibility and 
osteoconduction. It is a potential repairing material 
for clinical application205. The drawback in using 
these materials was that close proximity to the host 
bone was necessary to achieve osteoconduction. 
Advances in tissue engineering and the integration 
of the biological, physical, and engineering sciences, 
will create new carrier constructs that regenerate and 
restore functional state. These constructs are likely 
to encompass additional families of growth factors, 
evolving biological scaffolds, and incorporation of 
mesenchymal stem cells. Ultimately, the development 
of ex vivo bioreactors capable of bone manufacture 
with the appropriate biomechanical cues will provide 
tissue-engineered constructs for direct use in the 
skeletal system.
Conclusions
 Future biosynthetic bone implants may obviate 
the need for autologous bone grafts. There is 
increasing interest in combining an osteoconductive 
protein in an osteoconductive carrier medium to 
facilitate timed-release delivery and/or to provide 
a material scaffold for bone formation. Further, 
advances in tissue engineering, “the integration of 
the biological, physical and engineering sciences” 
will generate new carrier constructs that repair, 
regenerate and restore tissue to its functional state. 
These constructs are likely to encompass additional 
families of growth factors, evolving biological 
scaffolds and incorporation of mesenchymal stem 
cells. Ultimately, the development of ex vivo 
bioreactors capable of bone manufacture with the 
appropriate biomechanical cues will provide tissue-
engineered constructs for direct use in the skeletal 
system. Finally, as researchers continue to find new 
materials and biologic approaches to bone repair, the 
future of bone graft substitutes continues to be an 
expanding topic of interest.
References
Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. 1. 
Expert Rev Med Devices 2006; 3 : 49-57.
Pollock R, Alcelik I, Bhatia C, Chuter G, Lingutla K, 2. 
Budithi C, et al. Donor site morbidity following iliac crest 
bone harvesting for cervical fusion : a comparison between 
minimally invasive and open techniques. Eur Spine J 2008; 
17 : 845-52. 
Cowley SP, Anderson LD. Hernias through donor sites for 3. 
iliac-bone grafts. J Bone Joint Surg Am 1983; 65 : 1023-5.
Summers BN, Eisenstein SM. Donor site pain from the ilium. 4. 
A complication of lumbar spine fusion. J Bone Joint Surg Br 
1989; 71 : 677-80.
Friedlaender GE. Immune responses to osteochondral 5. 
allografts. Current knowledge and future directions. Clin 
Orthop Relat Res 1983; 174 : 58-68.
Perry CR. Bone repair techniques, bone graft and bone graft 6. 
substitutes. Clin Orthop Relat Res 1999; 360 : 71-86.
Samartzis 7. D, Shen FH, Goldberg EJ, An HS. Is autograft the 
gold standard in achieving radiographic fusion in one-level 
anterior cervical discectomy and fusion with rigid anterior 
plate fixation? Spine 2005; 30 : 1756-61. 
Bauer TW, Muschler GF. Bone graft materials : an overview 8. 
of the basic science. Clin Orthop Relat Res 2000; 371 : 10-
27.
Greenwald AS, Boden SD, Goldberg VM, Khan Y, Laurencin 9. 
CT, Rosier RN; American Academy of Orthopaedic Surgeons. 
The Committee on Biological implants. Bone-graft substitutes: 
facts, fictions, and applications. J Bone Joint Surg AM 2001; 
83-A (Suppl2) : 98-103.
Khan S10. N, Cammisa FP Jr, Sandhu HS, Diwan AD, Girardi FP, 
Lane JM. The biology of bone grafting. J Am Acad Orthop 
Surg 2005; 13 : 77-86. 
Sen MK, Miclau T. Autologous iliac crest bone graft : Should 11. 
it still be the gold standard for treating nonunions? Injury 
2007; 38 (Suppl 1): S75-S80.
Torroni A. Engineered bone grafts and bone flaps for 12. 
maxillofacial defects: state of the art. J Oral Maxillofac Surg 
2009; 67 : 1121-7.
Marx RE, Wong ME. A technique for the compression 13. 
and carriage of autogenous bone during bone 
grafting procedures. J Oral Maxillofac Surg 1987; 
 45 : 988-9.
Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to 14. 
autogenous bone graft : efficacy and indications. J Am Acad 
Orthop Surg 1995; 3 : 1-8.
Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz 15. 
MC. The expression of cytokine activity by fracture callus. 
J Bone Miner Res 1995; 10 : 1272-81.
 NANDI et al: BONE GRAFT & GRAFT SUBSTITUTES 25
Bisla RS, Singh K, Singh J, Chawla SK. Clinical and 16. 
radiographic studies on evaluation of entire segment cortical 
bone grafts in goats. Indian J Anim Sci 1991; 61 : 699-701.
Bacher JD, Schmidt RE. Effects of autogenous cancellous 17. 
bone on healing of homogenous cortical bone grafts. J Small 
Anim Pract 2008; 21 : 235-45.
Johnson LL, Morrison KM, Wood DL. The application of 18. 
arthroscopic principles to bone grafting of delayed union of 
long bone fractures. Arthroscopy 2000; 16 : 279-89.
Marsh JL. Principles of bone grafting: non-union, delayed 19. 
union. Surgery 2006; 24 : 207-10.
Welch RD, Zhang H, Bronson DG. Experimental tibial 20. 
plateau fractures augmented with calcium phosphate cement 
or autologous bone graft. J Bone Joint Surg Am 2003; 85A : 
222-31.
Dell PC, Burchardt H, Glowczewskie FP Jr. A roentgenographic, 21. 
biomechanical, and histological evaluation of vascularized 
and non-vascularized segmental fibular canine autografts. 
J Bone Joint Surg Am 1985; 67 : 105-12. 
Doi K, Tominaga S, Shibata T. Bone grafts with microvascular 22. 
anastomoses of vascular pedicles : an experimental study in 
dogs. J Bone Joint Surg Am 1977; 59 : 806-15.
Stevenson S. Biology of bone grafts23. . Orthop Clin North Am 
1999; 30 : 543-52.
Anderson KJ. The behavior of autogenous and homogenous 24. 
bone transplants in the anterior chamber of the rat’s eye. A 
histological study of the effect of the size of the implant. 
J Bone Joint Surg Am 1961; 43-A : 980-95. 
Beaman FD, Bancroft LW, Peterson JJ, Kransdorf MJ. Bone 25. 
graft materials and synthetic substitutes. Radiol Clin North 
Am 2006; 44 : 451-61. 
Finkemeier CG. Bone-grafting and bone-graft substitutes. 26. 
J Bone Joint Surg Am 2002; 84A : 454-64.
Putzier M, Strube P, Funk JF, Gross C, Mönig HJ, Perka C, 27. 
et al. Allogenic versus autologous cancellous bone in lumbar 
segmental spondylodesis: a randomized prospective study. 
Eur Spine J 2009; 18 : 687-95.
Marx RE. Bone and bone graft healing. 28. Oral Maxillofac Surg 
Clin North Am 2007; 19 : 455-66; v.
Romano CL, Romano D, Logoluso N. Low-intensity pulsed 29. 
ultrasound for the treatment of bone delayed union or nonunion 
: a review. Ultrasound Med Biol 2009; 35 : 529-36.
Kettunen J, Mäkelä EA, Turunen V, Suomalainen O, Partanen 30. 
K. Percutaneous bone grafting in the treatment of the delayed 
union and non-union of tibial fractures. Injury 2002; 33 : 239-
45.
Bohatyrewicz A, Bohatyrewicz R, Klęk R, Kamiński A, 31. 
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